Report of the ad hoc committee of the AAPM radiation therapy committee on 125I sealed source dosimetry.
OBJECTIVE
Two developments in 125I-sealed source dosimetry have necessitated swift and accurate implementation of TG43 dosimetry in clinic: (a) the dosimetry constants of 125I endorsed by the AAPM Task Group 43 Report result in calculated dose rate that deviates by as much as 15% from currently accepted dose-rate distributions, and (b) The National Institute of Standards and Technology (NIST) has proposed modifying the 125I air-kerma strength standard by approximately 10%.


METHODS
The ad hoc committee of AAPM Radiation Therapy Committee describes specific procedures to implement these two developments without causing confusion and mistakes.


CONCLUSIONS
Confusion and mistakes may be avoided when the following two general steps are taken: 1) STEP I, TG-43 implementation, and 2) STEP II, new air-kerma strength standard implementation when available from NIST.
Kubo
H D
HD
Department of Radiation Oncology, UC Davis Cancer Center, Sacramento, CA 95817, USA.
Coursey
B M
BM
Hanson
W F
WF
Kline
R W
RW
Seltzer
S M
SM
Shuping
R E
RE
Williamson
J F
JF
D001918:Brachytherapy / Q000295:instrumentation / Q000592:standards*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D018787:Radiation Oncology / Q000592:standards*; D011879:Radiotherapy Dosage / Q000592:standards; D012015:Reference Standards
D007457:Iodine Radioisotopes